Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis

Endocannabinoid system modulation for... | HRB Open Research dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); const cookieDomain = window.location.hostname; const tld = buildTLD(); function buildTLD() { const domainParts = cookieDomain.split('.'); while (domainParts.length > 2) { domainParts.shift(); } return domainParts.join('.'); } function deleteCookie(cookieName) { if (!cookieName) { return; } const cookiePath = (cookieName.startsWith('retraction_warning_') || cookieName.startsWith('version_warning_')) ? '/articles/' + cookieName : '/'; // Yes, these three slightly different ways to try and remove cookies are necessary document.cookie = cookieName + '=; path=' + cookiePath + '; domain=' + cookieDomain + '; expires=Thu, 01 Jan 1970 00:00:01 GMT;'; document.cookie = cookieName + '=; path=' + cookiePath + '; domain=.' + tld + '; expires=Thu, 01 Jan 1970 00:00:01 GMT;'; document.cookie = cookieName + '=; path=' + cookiePath + '; expires=Thu, 01 Jan 1970 00:00:01 GMT;'; } function deleteGroupCookies(group) { if (!group) { return; } const domainData = OneTrust.GetDomainData(), cookies = domainData.Groups.filter(cookieGroup => cookieGroup.OptanonGroupId === group)[0].Cookies; cookies.forEach(cookie => deleteCookie(cookie.Name)); } function OptanonWrapper() { const cookieConsentGroups = []; for (group of OneTrust.GetDomainData().Groups) { cookieConsentGroups.push(group.OptanonGroupId); } OneTrust.OnConsentChanged(function(e) { const cookieConsentActiveGroups = OnetrustActiveGroups.split(',').filter(activeGroup => activeGroup); cookieConsentGroups.forEach(group => { if (!cookieConsentActiveGroups.includes(group)) { deleteGroupCookies(group); }; }); }); } window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://hrbopenresearch.org/js/vendor/ckeditor/' window.reactTheme = 'HRB'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); Skip to content HRB Open Research file_upload Submit your research search clear search menu close clear Search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Data Guidelines Prepublication Checks Production Process Article Processing Charges Finding Article Reviewers About How it Works For Reviewers National Steering Group Policies Glossary FAQs Contact Blog My Account Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://hrbopenresearch.org/articles/8-40" }, "headline": "Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable...", "datePublished": "2025-03-13T19:44:41", "dateModified": "2025-07-23T15:16:31", "author": [ { "@type": "Person", "name": "Rebecca M. Lane" }, { "@type": "Person", "name": "Laurence J. Egan" }, { "@type": "Person", "name": "Brian E. McGuire" }, { "@type": "Person", "name": "Declan P. McKernan" }, { "@type": "Person", "name": "Siobhain M. O'Mahony" }, { "@type": "Person", "name": "David P. Finn" } ], "publisher": { "@type": "Organization", "name": "HRB Open Research", "logo": { "@type": "ImageObject", "url": "https://hrbopenresearch.org/img/AMP/HRB_image.png", "height": 566, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://hrbopenresearch.org/img/AMP/HRB_image.png", "height": 1200, "width": 127 }, "description": "Visceral Pain is a common debilitating symptom of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). The endocannabinoid system (ECS) is a prime target for alleviation of visceral pain, given its important role in both gastrointestinal physiology and pain. We will conduct a systematic review of randomised controlled trials (RCTs) of cannabis, cannabinoids, cannabis-based medicines (CBMs), and other ECS modulators for patients with IBD and IBS, comparing any preparation of cannabis, any cannabinoid, CBM, or other pharmacological modulator of the ECS (any dose, by any route of administration), with any control (placebo, or pharmacological / psychological / dietary intervention). We will search CENTRAL, MEDLINE, PubMed, EMBASE, and Web of Science databases, as well as the WHO International Clinical Trials Registry Platform and ClinicalTrials.gov Trials Registries, together with reference checking and citation searching, following PRISMA guidelines. Our objectives are to evaluate the benefits and harms of pharmacological modulation of the ECS for visceral abdominal pain in patients with IBD or IBS, compared to placebo or other interventions. The primary outcomes will be the proportion of people with (a) at least a 30% reduction and (b) at least a 50% reduction in pain. Secondary outcomes will include any change in pain intensity, physical and emotional functioning, fatigue and sleep measures, quality of life, gastrointestinal disease or symptom severity, and adverse effects. We will assess risk of bias in the RCTs using the Cochrane Risk of Bias 2 tool. Where there are sufficient data that are directly comparable, we will conduct meta-analyses of the results for each outcome. We will use the GRADEpro GDT tool to assess certainty of evidence for each outcome. This review will synthesise the available evidence regarding all types of ECS modulation for the treatment of visceral abdominal pain and its related comorbidities in IBS and IBD patients." } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://hrbopenresearch.org/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://hrbopenresearch.org/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://hrbopenresearch.org/articles/8-40/v2", "name": "Endocannabinoid system modulation for visceral abdominal pain in inflammatory..." } } ] } Home Browse Endocannabinoid system modulation for visceral abdominal pain in inflammatory... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Lane RM, Egan LJ, McGuire BE et al. Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] . HRB Open Res 2025, 8 :40 ( https://doi.org/10.12688/hrbopenres.14082.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Study Protocol Revised Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] Rebecca M. Lane https://orcid.org/0009-0004-9301-6083 1-3 , Laurence J. Egan 1,4 , Brian E. McGuire 2,3,5 , Declan P. McKernan https://orcid.org/0000-0002-9691-1671 1-3 , Siobhain M. O'Mahony 6 , David P. Finn https://orcid.org/0000-0001-6186-621X 1-3 Rebecca M. Lane https://orcid.org/0009-0004-9301-6083 1-3 , Laurence J. Egan 1,4 , [...] Brian E. McGuire 2,3,5 , Declan P. McKernan https://orcid.org/0000-0002-9691-1671 1-3 , Siobhain M. O'Mahony 6 , David P. Finn https://orcid.org/0000-0001-6186-621X 1-3 PUBLISHED 23 Jul 2025 Author details Author details 1 Pharmacology and Therapeutics, School of Medicine, University of Galway, Galway, Ireland 2 Centre for Pain Research, University of Galway, Galway, Ireland 3 Galway Neuroscience Centre, University of Galway, Galway, Ireland 4 Gastroenterology, Galway University Hospital, Galway, Ireland 5 School of Psychology, University of Galway, Galway, Ireland 6 Anatomy and Neuroscience, University College Cork and APC Microbiome Ireland, Cork, Ireland Rebecca M. Lane Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation Laurence J. Egan Roles: Supervision, Writing – Review & Editing Brian E. McGuire Roles: Supervision, Writing – Review & Editing Declan P. McKernan Roles: Supervision, Writing – Review & Editing Siobhain M. O'Mahony Roles: Writing – Review & Editing David P. Finn Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Visceral Pain is a common debilitating symptom of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). The endocannabinoid system (ECS) is a prime target for alleviation of visceral pain, given its important role in both gastrointestinal physiology and pain. We will conduct a systematic review of randomised controlled trials (RCTs) of cannabis, cannabinoids, cannabis-based medicines (CBMs), and other ECS modulators for patients with IBD and IBS, comparing any preparation of cannabis, any cannabinoid, CBM, or other pharmacological modulator of the ECS (any dose, by any route of administration), with any control (placebo, or pharmacological / psychological / dietary intervention). We will search CENTRAL, MEDLINE, PubMed, EMBASE, and Web of Science databases, as well as the WHO International Clinical Trials Registry Platform and ClinicalTrials.gov Trials Registries, together with reference checking and citation searching, following PRISMA guidelines. Our objectives are to evaluate the benefits and harms of pharmacological modulation of the ECS for visceral abdominal pain in patients with IBD or IBS, compared to placebo or other interventions. The primary outcomes will be the proportion of people with (a) at least a 30% reduction and (b) at least a 50% reduction in pain. Secondary outcomes will include any change in pain intensity, physical and emotional functioning, fatigue and sleep measures, quality of life, gastrointestinal disease or symptom severity, and adverse effects. We will assess risk of bias in the RCTs using the Cochrane Risk of Bias 2 tool. Where there are sufficient data that are directly comparable, we will conduct meta-analyses of the results for each outcome. We will use the GRADEpro GDT tool to assess certainty of evidence for each outcome. This review will synthesise the available evidence regarding all types of ECS modulation for the treatment of visceral abdominal pain and its related comorbidities in IBS and IBD patients. READ ALL READ LESS Keywords Visceral Pain, Abdominal Pain, Endocannabinoid System, IBD, IBS, Cannabis, Cannabinoid, Cannabis-Based Medicine Corresponding Author(s) David P. Finn ( [email protected] ) Close Corresponding author: David P. Finn Competing interests: D.P. Finn reports grant funding from B. Braun Ltd, outside the submitted work. Grant information: This work is funded by Taighde Éireann –Research Ireland [GOIPG/2024/4981]. This work was also supported by the University of Galway Hardiman Research Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2025 Lane RM et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Lane RM, Egan LJ, McGuire BE et al. Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] . HRB Open Res 2025, 8 :40 ( https://doi.org/10.12688/hrbopenres.14082.2 ) First published: 13 Mar 2025, 8 :40 ( https://doi.org/10.12688/hrbopenres.14082.1 ) Latest published: 23 Jul 2025, 8 :40 ( https://doi.org/10.12688/hrbopenres.14082.2 ) Revised Amendments from Version 1 This version of the manuscript addresses all comments received from the reviewers on version 1. The main revisions include the addition of some references, minor edits to phraseology in places, clarification on what is meant by 'other ECS modulators', and the inclusion of 'indeterminate colitis' under IBD. This version of the manuscript addresses all comments received from the reviewers on version 1. The main revisions include the addition of some references, minor edits to phraseology in places, clarification on what is meant by 'other ECS modulators', and the inclusion of 'indeterminate colitis' under IBD. See the authors' detailed response to the review by Colm B Collins See the authors' detailed response to the review by Simon Erridge READ REVIEWER RESPONSES Background Visceral abdominal pain in IBS and IBD Chronic visceral abdominal pain is a cardinal diagnostic criterion of irritable bowel syndrome (IBS) 1 , and affects up to 60% of patients with inflammatory bowel disease (IBD) irrespective of their disease activity 2 , 3 . In addition to the negative impact of chronic pain itself 4 , the health-related quality of life of these patients is further impacted by highly prevalent comorbidities of chronic pain, including anxiety and depression 5 – 7 , and fatigue 8 – 10 . There is a sex dimorphism in visceral pain in IBS and IBD, with IBS more prevalent in females 11 , and female sex an independent risk factor for pain in IBD 12 . Adequate treatment of abdominal pain remains challenging 13 . Adverse effects of commonly used analgesics (e.g., aspirin and other non-steroidal anti-inflammatory drugs, opioids) on the gastrointestinal tract are of particular concern in these patient populations 14 , 15 . Furthermore, chronic use of some analgesics, such as opioids, could lead to dependence and opioid-induced hyperalgesia 16 . The overlap between IBS and IBD with regards visceral pain and its treatment is apparent, as is the utility of taking the lead from the IBS research, which has investigated promising avenues for pain management like anti-spasmodic (e.g. hyoscyamine), anti-convulsant (e.g. gabapentin, pregabalin) and psychopharmacological agents (e.g. tricyclic-antidepressants, selective serotonin reuptake inhibitors, serotonin-noradrenaline reuptake inhibitors) 17 , 18 . For both IBS and IBD, a holistic approach to pain management is ultimately required, one that incorporates new pharmacological therapies that target the underlying pain pathophysiology, alongside a tailored selection of dietary, psychological, and lifestyle interventions 19 , 20 . The Endocannabinoid System (ECS) Modulation of the sexually dimorphic ECS 21 , an endogenous pain control system, presents a novel avenue for management of pain and negative affective comorbidities in IBS and IBD 22 – 24 . The ECS consists of G i/o -coupled cannabinoid receptors 1 and 2 (CB 1 and CB 2 ) 25 – 27 , their endogenous lipid ligands ‘endocannabinoids’ anandamide (AEA) 28 , and 2-arachydonyl glycerol (2-AG) 29 , 30 , related-lipids N- oleoylethanolamide (OEA), and N- palmitoylethanolamide (PEA) 28 – 30 and a plethora of catabolic and anabolic enzymes, for example, fatty acid amide hydrolase (FAAH) which degrades AEA, PEA, and OEA 31 , and monoacylglycerol lipase (MGL) which degrades 2-AG 32 . The ECS is situated at peripheral, spinal and supra-spinal levels of the pain pathways 22 . It is also present in neuronal and non-neuronal tissue of the gastrointestinal tract where it functions to maintain homeostasis, regulating processes such as visceral sensitivity, inflammation, motility, and secretion 33 . Importantly, individuals with IBS and IBD have been shown to have significant alterations in their ECS compared to healthy controls, making this system a key target for treatment of their visceral pain. These alterations range from variation in genes encoding cannabinoid receptors and endocannabinoid-metabolising enzymes 34 – 36 , to differing expression of mRNA 24 , 37 – 41 and proteins related to the ECS 37 and differing levels of circulating endocannabinoids 24 , 38 , 40 . Cannabis, cannabinoids and cannabis-based medicines There are a variety of natural and synthetic compounds that can modulate the ECS. The natural compounds are derived from Cannabis sativa plant material including herbal cannabis/marijuana, pharmaceutical grade medicinal cannabis, or extracts, and include individual phytocannabinoids (most notably, delta 9-tetrahydrocannabinol [THC] 42 and cannabidiol [CBD] 43 ). Certain extracts with specific concentrations of THC and/or CBD have regulatory approval and are classified as ‘cannabis-based medicines’ (CBMs, e.g., nabiximols 44 , CBD 45 ). The synthetic compounds, some of which are still under development, include a variety of ECS modulators: cannabinoid receptor agonists (e.g., nabilone 46 , dronabinol 47 , CT-3 48 ), cannabinoid receptor antagonists (e.g., Rimonabant 49 ), and enzyme inhibitors (e.g., PF-00457845 50 ). While there are a variety of compounds or formulations, few have been thoroughly tested in randomised controlled clinical trials (RCTs), and even fewer are approved by regulatory authorities for pain management, as clinical evidence for their effectiveness is limited 51 . Study of ECS modulators is further complicated by the large variety of formulations, doses, and routes of administration available (e.g., oral, oromucosal, inhaled), making comparisons between trials difficult. Despite this, use of ECS modulators (mostly medicinal cannabis) is common amongst patients with pain, including those with IBS and IBD 52 – 54 . Importance of this review Previous reviews in this area have investigated the impact of ECS modulators for IBS or IBD generally 55 – 58 , but there has been very little recognition of pain as a key outcome measure, despite the heavy burden this symptom places on patients and its relationship with emotional and physical functioning and quality of life scores. This review will place pain at the forefront, with keen attention also paid to comorbidities of chronic pain. Furthermore, previous reviews have had quite selective search terms, thus focusing on subsets of ECS modulators 56 , 57 rather than assessing all types of ECS modulators, as this review aims to do. Finally, this review, in compiling the literature on ECS modulators across both IBS and IBD, may reveal important findings with regards similarities and differences in the response to ECS modulators between the different, yet related, populations. Objectives The primary objective of this systematic review of RCTs will be to assess the effects of cannabis, cannabinoids, CBMs, and other ECS modulators for visceral abdominal pain in patients with IBS and IBD, providing estimates of effectiveness and adverse effects. The primary outcome measures will be the proportion of people with (a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity (measured using a 0–10 numerical rating scale). We have chosen these specific percentage reductions as their clinical significance is supported by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) 59 . Key secondary objectives will include assessing the effects of cannabis, cannabinoids, CBMs and other ECS modulators on pain intensity (measured by verbal, visual, or numerical pain rating scale), pain interference, physical functioning, emotional functioning, fatigue and sleep, overall quality of life, and gastrointestinal health. Methods We will follow the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines 60 . Criteria for considering studies Studies We will include RCTs conducted in any care setting, in any part of the world, in this systematic review. Participants We will include participants, of any age, sex, or ethnicity, with a diagnosis of IBS as defined by ROME III/IV guidelines 1 and/or IBD as defined by ECCO-ESGAR guidelines 61 . Interventions and comparisons We will include any type of cannabis, cannabinoid, CBM or ECS modulator, at any dose, delivered by any route of administration, for any duration. We will also include any trials that administer cannabis, cannabinoids, CBMs or ECS modulators as part of a combination treatment, with one another or with other drugs. We will include any control; placebo, or pharmacological/psychological/dietary interventions. We will base comparisons on the interventions grouped as follows: Cannabis Cannabinoids CBMs Other ECS modulators (e.g., cannabinoid receptor antagonists; ECS enzyme inhibitors, modulators or substrates) Placebo Alternative intervention: pharmacological, psychological, dietary We will differentiate between interventions that have a sole aim of reducing pain intensity, and those that aim to improve IBS/IBD health outcomes more generally. Outcomes Table 1 provides a summary of the outcome measures for each of the outcome domains listed below. Table 1. Summary of outcome measures. Broad outcome grouping Outcome domain Outcome measures Pain Pain Intensity Numerical pain rating scale (primary outcomes) Visual or verbal pain rating scale (secondary outcome) Quality of Life Quality of life Quality-of-life score (e.g., short form-36, IBDQ 32, IBS-QOL) Physical Functioning Pain Interference Interference scales of the Multidimensional Pain Inventory or Brief Pain Inventory Fatigue Fatigue scores (e.g., Fatigue Severity Scales) Sleep Sleep Scores (e.g., Pittsburgh Sleep Quality Index, Bergen Insomnia Scale, Mini-Sleep Questionnaire) Emotional Functioning Depression Depression rating scale (e.g. BDI, HAM-D, PHQ-9) Anxiety Anxiety rating scale (e.g., STAI, HAM-A, GAD-7) Gastrointestinal Health Disease severity Standard use scale (e.g., CDAI, HBI, Mayo score), Clinical measurement (biochemical or endoscopic measures of inflammation) Symptoms Symptom scales (IBS-SSS) Analgesic effects Onset Duration Rescue Analgesia Requirement for rescue analgesia Type of rescue analgesia used Timepoint at which rescue analgesia was required Duration of rescue analgesia Change to analgesia used as part of usual care Was this type of analgesia already used as part of usual care? Adverse Events Measures of Harm Withdrawal due to serious AEs Withdrawal due to AEs Patients reporting any AE BDI; Beck Depression Inventory, HAM-D; Hamilton Depression Rating Scale, PHQ-9; Patient Health Questionnaire-9, STAI; State-Trait Anxiety Inventory, HAM-A; Hamilton Anxiety Rating Scale, GAD-7; Generalised Anxiety Disorder, IBDQ32; IBD Questionnaire 32, IBS-QOL; IBS Quality of Life Questionnaire, CDAI; Crohn's Disease Activity Index, HBI; Harvey-Bradshaw Index, IBS-SSS; IBS Symptom Severity Scale. Primary outcomes i. The proportion of people with at least 30% reduction in pain intensity ii. The proportion of people with at least 50% reduction in pain intensity Secondary outcomes i. Changes in pain intensity ii. Change in quality of life iii. Change in physical functioning measures (incl. pain interference, fatigue and sleep measures) iv. Change in emotional functioning measures (e.g. anxiety, depression, mood etc.) v. Changes in gastrointestinal health measures (incl. disease and symptom severity) vi. Adverse events (AEs): AEs will include measures of harm, including withdrawal due to serious AEs, withdrawal because of AEs, patients reporting any AE. Following the PRISMA Harms Checklist 62 , we will describe how AEs were addressed, how they were reported, and over what period the harm was experienced. vii. Requirement for rescue analgesia or change in dose of analgesia taken as part of usual care. viii. Onset and duration of analgesic effects Exclusion criteria We will exclude: (1) studies that are not RCTs (e.g. cohort studies, case-control studies, cross-sectional studies), (2) grey literature, conference abstracts or case reports, (3) studies not published in the English language, or where the full text is not available in the English language. Data collection and analysis Search methods for identification of studies We will search the literature using a staged approach. We will search CENTRAL, MEDLINE, PubMed, EMBASE, and Web of Science databases from inception to present for peer-reviewed publications with limit to publications available in the English language (see extended data for search strategy). We will search the World Health Organisation International Clinical Trials Registry Platform and the ClinicalTrials.gov online clinical trials registries. We will conduct reference checking and citation searching of included publications to search for further trials. If we identify systematic reviews in the field, we will search their reference lists. We will not search for non-RCT studies (e.g., cohort studies, case-control studies, cross-sectional studies), grey literature or conference abstracts. We will endeavour to match selected RCTs with their trial identifier. Selection of studies Two authors will independently decide which of the identified trials will be selected for screening based on their titles and abstracts. Disagreements will be resolved by discussion between the two authors, or with a third author if necessary. We will retrieve the full text of any publications or reports identified as potentially relevant. Two authors will independently screen the full texts for inclusion against eligibility criteria. Disagreements will be resolved by discussion between the two authors, or with a third author if necessary. We will include any peer-reviewed publication or online trial registration that investigated the therapeutic effects of cannabis, cannabinoids, CBMs or other ECS modulators, given by any dose or route of administration, for any duration, compared with placebo, or active pharmacological, psychological, or dietary intervention, for improving health outcomes in IBS and/or IBD patients, irrespective of reported measures. We will manage the results of our search using the Rayyan online systematic review software package (this is a proprietary tool; open access alternatives are provided in the Software Availability section). We will document our screening and selection process in sufficient detail to complete a PRISMA flow chart and ‘Characteristics of excluded studies’ table. We will include trials that are registered but not yet published as ‘awaiting classification’ and describe them separately to the included studies. Data extraction and management Two authors will independently extract the following data from the included trials using a data extraction spreadsheet on Microsoft Excel: General information: journal, reference, corresponding author, year, country where study was conducted. Study characteristics: aims, design, participants enrolled per arm, enrolment method, inclusion/exclusion criteria, length of follow up (including potential sources of bias). Participant characteristics: age, sex, comorbidities, current medications, absence/presence of pain. IBS/IBD classification: diagnostic criteria/guidelines used (IBS: ROME II, III, IV; IBD: ECCO-ESGAR, AGA etc.), subtype (IBS: constipation predominant [C], diarrhoea predominant [D] or mixed symptoms [M]; IBD: Crohn’s disease [CD], ulcerative colitis [UC], indeterminate colitis [IC]), and severity. Intervention and comparator characteristics: type of ECS modulator/comparator, dose, duration, route of administration. Outcomes: we will extract any outcomes listed in the primary and secondary outcomes of this protocol. Disagreements will be resolved by discussion between the two authors, or with a third author if necessary. We will contact study authors of trials included in the review if required to obtain further data or to confirm aspects of the data available. One author will enter all extracted data into the Review Manager (RevMan) web platform (this is a proprietary tool; open access alternatives are provided in the Software Availability section). A second author will independently check the entered data for accuracy. Risk of bias (quality) assessment of included studies Two authors will independently assess the risk of bias of included trials using the Cochrane Risk of Bias Tool (RoB2) (Creative Commons Attribution-Non Commercial-No Derivatives 4.0 International License) 63 . Disagreements will be resolved by discussion between the two authors, or with a third author if necessary. We will report our judgements with supporting quotes and justifications on the following risk of bias domains in a risk of bias table: random sequence generation (selection bias); allocation concealment (selection bias); blinding of participants and personnel (performance bias) and blinding of outcome assessment (detection bias); completeness of outcome data (attrition bias), selective outcome reporting (reporting bias), and study size (bias of small size). Our judgements on a trial being of high, low, or some concern for risk of bias will follow criteria set out in the Cochrane Handbook for Systematic Reviews of Interventions 64 and in the Cochrane Pain, Palliative, and Supportive Care Review Group template for intervention review 65 . Synthesis methods We will tabulate two descriptive summaries of the extracted data from individual trials: one for IBS trials, and one for IBD trials. These tables will include participant characteristics, post-treatment N, length of follow up, and descriptions of interventions, comparators, duration, and outcome measures of interest for this review, including adverse event description and frequency. We will stratify by IBS and IBD classification (IBS-C/IBS-D/IBS-M and CD/UC/IC, respectively), and intervention type (cannabis, cannabinoid, CBM, other pharmacological ECS modulator), if possible. We will narratively compare the effects of ECS modulation for outcomes relevant to both IBS and IBD populations (e.g., pain intensity, physical and emotional functioning, quality of life, fatigue, sleep, adverse events). This will enable us to identify similarities and differences between the included trials for each condition and across both conditions. We will combine data comparing ECS modulation versus control for IBS or IBD respectively in meta-analysis if sufficient data on similar outcomes from homogenous studies are available. Two authors will independently select studies suitable for inclusion in meta-analysis, with any disagreements resolved by discussion with a third author. We will only include studies with greater than 30 participants post-treatment per group in the meta-analysis, as small sample sizes can inflate effect estimates 51 , 66 . We will use Review Manager (RevMan) for meta-analysis. We will calculate standardised mean differences with 95% confidence interval (CI) for continuous outcomes, and risk ratio with 95% CI for dichotomous outcomes. We will also calculate risk ratios with 95% confidence intervals for adverse events. We will perform statistical analysis using a random effects model to account for any within-study and between study-variation. We will assess statistical heterogeneity using the I 2 statistic. We will conduct sensitivity analysis to examine the impact of risk of bias and certainty of evidence. If the data allows, we will perform the following subgroup analysis: i Classification of IBS: IBS-C, IBS-D, IBS-M ii Diagnostic criteria of IBS: ROME III, ROME IV iii Classification of IBD: CD, UC, IC iv Intervention type v Comparator type vi Length of follow up vii Treatment duration If meta-analysis is not possible due to the nature of the data available, we will synthesize the literature narratively and will create effect direction plots for our outcomes of interest. Certainty of the evidence assessment (GRADE) Two authors will assess the certainty of the evidence using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach, and the GRADEpro GDT tool (Standard Licence) 67 , 68 . The GRADE approach deems the certainty of evidence for each outcome to be ‘high’, ‘moderate’, ‘low’ or ‘very low’ based on 5 considerations: study limitations, unexplained heterogeneity or inconsistency, imprecision, indirectness and publication bias. Disagreements will be resolved by discussion between the two authors, or with a third author if necessary. Data availability Underlying data No data are associated with this article. Extended data Open Science Framework: Systematic review of endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome. https://doi.org/10.17605/OSF.IO/PJTVU 69 . This project contains the following extended data: Abdominal pain_Medline search_original_10 Dec 24 (search strategy for MEDLINE) Abdominal pain_free software alternatives_10 Feb 25 Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication). Reporting guidelines Open Science Framework: PRISMA-P checklist for ‘Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis’. https://doi.org/10.17605/OSF.IO/PJTVU 69 . Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication). Contributions of authors R.M.L. Conceptualization, Writing - original draft preparation, Writing - review & editing, Funding acquisition. D.P.F. Conceptualization, Writing - review & editing, Funding acquisition. L.J.E., B.E.McG., D.P.McK., S.M.O’M. Writing - review & editing Faculty Opinions recommended References 1. Lacy BE, Mearin F, Chang L, et al. : Bowel disorders. Gastroenterology. 2016; 150 (6): 1393–1407.e5. Publisher Full Text 2. Coates MD, Johri A, Gorrepati VS, et al. : Abdominal pain in quiescent Inflammatory Bowel Disease. Int J Colorectal Dis. 2021; 36 (1): 93–102. PubMed Abstract | Publisher Full Text | Free Full Text 3. Lönnfors S, Vermeire S, Greco M, et al. : IBD and Health-Related Quality of Life -- discovering the true impact. J Crohns Colitis. 2014; 8 (10): 1281–1286. PubMed Abstract | Publisher Full Text 4. Schirbel A, Reichert A, Roll S, et al. : Impact of pain on Health-Related Quality of Life in patients with Inflammatory Bowel Disease. World J Gastroenterol. 2010; 16 (25): 3168–77. PubMed Abstract | Publisher Full Text | Free Full Text 5. Zamani M, Alizadeh-Tabari S, Zamani V: Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2019; 50 (2): 132–143. PubMed Abstract | Publisher Full Text 6. Mikocka-Walus A, Knowles SR, Keefer L, et al. : Controversies revisited: a systematic review of the comorbidity of depression and anxiety with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016; 22 (3): 752–62. PubMed Abstract | Publisher Full Text 7. Lee C, Doo E, Choi JM, et al. : The increased level of depression and anxiety in Irritable Bowel Syndrome patients compared with healthy controls: systematic review and meta-analysis. J Neurogastroenterol Motil. 2017; 23 (3): 349–362. PubMed Abstract | Publisher Full Text | Free Full Text 8. Jelsness-Jørgensen LP, Bernklev T, Henriksen M, et al. : Chronic fatigue is associated with impaired Health-Related Quality of Life in Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2011; 33 (1): 106–114. PubMed Abstract | Publisher Full Text 9. Han CJ, Yang GS: Fatigue in Irritable Bowel Syndrome: a systematic review and meta-analysis of pooled frequency and severity of fatigue. Asian Nurs Res (Korean Soc Nurs Sci). 2016; 10 (1): 1–10. PubMed Abstract | Publisher Full Text 10. Lackner JM, Gudleski GD, Dimuro J, et al. : Psychosocial predictors of self-reported fatigue in patients with moderate to severe Irritable Bowel Syndrome. Behav Res Ther. 2013; 51 (6): 323–31. PubMed Abstract | Publisher Full Text | Free Full Text 11. Houghton LA, Heitkemper M, Crowell M, et al. : Age, gender and women's health and the patient. Gastroenterology. 2016; 150 (6): 1332–1343.e4. PubMed Abstract | Publisher Full Text 12. Hardy PY, Fikri J, Libbrecht D, et al. : Pain characteristics in patients with Inflammatory Bowel Disease: a monocentric cross-sectional study. J Crohns Colitis. 2022; 16 (9): 1363–1371. PubMed Abstract | Publisher Full Text 13. Zeitz J, Ak M, Müller-Mottet S, et al. : Pain in IBD patients: very frequent and frequently insufficiently taken into account. PLoS One. 2016; 11 (6): e0156666. PubMed Abstract | Publisher Full Text | Free Full Text 14. Moninuola OO, Milligan W, Lochhead P, et al. : Systematic review with meta-analysis: association between acetaminophen and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and risk of Crohn's Disease and Ulcerative Colitis exacerbation. Aliment Pharmacol Ther. 2018; 47 (11): 1428–1439. PubMed Abstract | Publisher Full Text | Free Full Text 15. Kurlander JE, Drossman DA: Diagnosis and treatment of Narcotic Bowel Syndrome. Nat Rev Gastroenterol Hepatol. 2014; 11 (7): 410–8. PubMed Abstract | Publisher Full Text 16. Ballantyne JC, LaForge SK: Opioid dependence and addiction during opioid treatment of chronic pain. Pain. 2007; 129 (3): 235–255. PubMed Abstract | Publisher Full Text 17. Grover M, Drossman D: Pain management in IBD. Inflammatory Bowel Disease Monitor. 2009; 10 : 1–10. Reference Source 18. Chen L, Ilham SJ, Feng B: Pharmacological approach for managing pain in Irritable Bowel Syndrome: a review article. Anesth Pain Med. 2017; 7 (2): e42747. PubMed Abstract | Publisher Full Text | Free Full Text 19. Paine P: Review article: current and future treatment approaches for pain in IBS. Aliment Pharmacol Ther. 2021; 54 (S1): S75–S88. PubMed Abstract | Publisher Full Text 20. Baillie S, Norton C, Saxena S, et al. : Chronic abdominal pain in Inflammatory Bowel Disease: a practical guide. Frontline Gastroenterol. 2023; 15 (2): 144–153. PubMed Abstract | Publisher Full Text | Free Full Text 21. Amir Hamzah K, Toms LM, Kucharski N, et al. : Sex-dimorphism in human serum endocannabinoid and n-acyl ethanolamine concentrations across the lifespan. Sci Rep. 2023; 13 (1): 23059. PubMed Abstract | Publisher Full Text | Free Full Text 22. Woodhams SG, Chapman V, Finn DP, et al. : The cannabinoid system and pain. Neuropharmacology. 2017; 124 : 105–120. PubMed Abstract | Publisher Full Text | Free Full Text 23. Storr MA, Yüce B, Andrews CN, et al. : The role of the Endocannabinoid System in the pathophysiology and treatment of Irritable Bowel Syndrome. Neurogastroenterol Motil. 2008; 20 (8): 857–868. PubMed Abstract | Publisher Full Text 24. Hryhorowicz S, Kaczmarek-Ryś M, Zielińska A, et al. : Endocannabinoid System as a promising therapeutic target in Inflammatory Bowel Disease - a systematic review. Front Immunol. 2021; 12 : 790803. PubMed Abstract | Publisher Full Text | Free Full Text 25. Devane WA, Dysarz FA 3rd, Johnson MR, et al. : Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988; 34 (5): 605–13. PubMed Abstract | Publisher Full Text 26. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365 (6441): 61–5. PubMed Abstract | Publisher Full Text 27. Glass M, Dragunow M, Faull RL: Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997; 77 (2): 299–318. PubMed Abstract | Publisher Full Text 28. Devane WA, Hanus L, Breuer A, et al. : Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258 (5090): 1946–1949. PubMed Abstract | Publisher Full Text 29. Mechoulam R, Ben-Shabat S, Hanus L, et al. : Identification of an endogenous 2–monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995; 50 (1): 83–90. PubMed Abstract | Publisher Full Text 30. Sugiura T, Kondo S, Sukagawa A, et al. : 2–Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995; 215 (1): 89–97. PubMed Abstract | Publisher Full Text 31. Cravatt BF, Demarest K, Patricelli MP, et al. : Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking Fatty Acid Amide Hydrolase. Proc Natl Acad Sci U S A. 2001; 98 (16): 9371–9376. PubMed Abstract | Publisher Full Text | Free Full Text 32. Dinh TP, Carpenter D, Leslie FM, et al. : Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002; 99 (16): 10819–10824. PubMed Abstract | Publisher Full Text | Free Full Text 33. Sharkey KA, Wiley JW: The role of the Endocannabinoid System in the brain-gut axis. Gastroenterology. 2016; 151 (2): 252–66. PubMed Abstract | Publisher Full Text | Free Full Text 34. Park JM, Choi MG, Cho YK, et al. : Cannabinoid receptor 1 gene polymorphism and Irritable Bowel Syndrome in the Korean population: a hypothesis-generating study. J Clin Gastroenterol. 2011; 45 (1): 45–9. PubMed Abstract | Publisher Full Text 35. Camilleri M, Kolar GJ, Vazquez-Roque MI, et al. : Cannabinoid receptor 1 gene and Irritable Bowel Syndrome: phenotype and quantitative traits. Am J Physiol Gastrointest Liver Physiol. 2013; 304 (5): G553–60. PubMed Abstract | Publisher Full Text | Free Full Text 36. Camilleri M, Carlson P, McKinzie S, et al. : Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am J Physiol Gastrointest Liver Physiol. 2008; 294 (1): G13–9. PubMed Abstract | Publisher Full Text 37. Dothel G, Chang L, Shih W, et al. : µ-opioid receptor, β-endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of Irritable Bowel Syndrome patients. Neurogastroenterol Motil. 2019; 31 (11): e13688. PubMed Abstract | Publisher Full Text | Free Full Text 38. Fichna J, Wood JT, Papanastasiou M, et al. : Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. PLoS One. 2013; 8 (12): e85073. PubMed Abstract | Publisher Full Text | Free Full Text 39. Stintzing S, Wissniowski TT, Lohwasser C, et al. : Role of cannabinoid receptors and RAGE in Inflammatory Bowel Disease. Histol Histopathol. 2011; 26 (6): 735–45. PubMed Abstract | Publisher Full Text 40. Grill M, Högenauer C, Blesl A, et al. : Members of the Endocannabinoid System are distinctly regulated in Inflammatory Bowel Disease and Colorectal Cancer. Sci Rep. 2019; 9 (1): 2358. PubMed Abstract | Publisher Full Text | Free Full Text 41. Leinwand KL, Jones AA, Huang RH, et al. : Cannabinoid receptor-2 ameliorates inflammation in murine model of Crohn's disease. J Crohns Colitis. 2017; 11 (11): 1369–1380. PubMed Abstract | Publisher Full Text | Free Full Text 42. Mechoulam R, Gaoni Y: The absolute configuration of δ 1 –tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett. 1967; 12 : 1109–11. PubMed Abstract | Publisher Full Text 43. Britch SC, Babalonis S, Walsh SL: Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl). 2021; 238 (1): 9–28. PubMed Abstract | Publisher Full Text | Free Full Text 44. Kleiner D, Horváth IL, Bunduc S, et al. : Nabiximols is efficient as add-on treatment for patients with Multiple Sclerosis spasticity refractory to standard treatment: a systematic review and meta-analysis of Randomised Clinical Trials. Curr Neuropharmacol. 2023; 21 (12): 2505–2515. PubMed Abstract | Publisher Full Text | Free Full Text 45. Devinsky O, Cross JH, Laux L, et al. : Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017; 376 (21): 2011–2020. PubMed Abstract | Publisher Full Text 46. Tsang CC, Giudice MG: Nabilone for the management of pain. Pharmacotherapy. 2016; 36 (3): 273–286. PubMed Abstract | Publisher Full Text 47. Schimrigk S, Marziniak M, Neubauer C, et al. : Dronabinol is a safe long-term treatment option for neuropathic pain patients. Eur Neurol. 2017; 78 (5–6): 320–329. PubMed Abstract | Publisher Full Text | Free Full Text 48. Karst M, Salim K, Burstein S, et al. : Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a Randomized Controlled Trial. JAMA. 2003; 290 (13): 1757–62. PubMed Abstract | Publisher Full Text 49. Després JP, Ross R, Boka G, et al. : Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol. 2009; 29 (3): 416–23. PubMed Abstract | Publisher Full Text 50. D'Souza DC, Cortes-Briones J, Creatura G, et al. : Efficacy and safety of a Fatty Acid Amide Hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site Randomised Controlled Trial. Lancet Psychiatry. 2019; 6 (1): 35–45. PubMed Abstract | Publisher Full Text 51. Fisher E, Moore RA, Fogarty AE, et al. : Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of Randomised Controlled Trials. Pain. 2021; 162 (Suppl 1): S45–S66. PubMed Abstract | Publisher Full Text 52. Appleton K, Whittaker E, Cohen Z, et al. : Attitudes towards and use of cannabis in New Zealand patients with Inflammatory Bowel Disease: an exploratory study. N Z Med J. 2021; 134 (1530): 38–47. PubMed Abstract 53. El-Dallal M, Anderson KL, Saroufim A, et al. : Patients' perspectives on marijuana use for Inflammatory Bowel Disease: a multicenter survey. Ann Gastroenterol. 2023; 36 (6): 624–629. PubMed Abstract | Publisher Full Text | Free Full Text 54. Desai P, Mbachi C, Vohra I, et al. : Association between cannabis use and healthcare utilization in patients with Irritable Bowel Syndrome: a retrospective cohort study. Cureus. 2020; 12 (5): e8008. PubMed Abstract | Publisher Full Text | Free Full Text 55. Doeve BH, van de Meeberg MM, van Schaik FDM, et al. : A systematic review with meta-analysis of the efficacy of cannabis and cannabinoids for Inflammatory Bowel Disease: what can we learn from randomized and nonrandomized studies? J Clin Gastroenterol. 2021; 55 (9): 798–809. PubMed Abstract | Publisher Full Text 56. Pandey S, Kashif S, Youssef M, et al. : Endocannabinoid System in Irritable Bowel Syndrome and cannabis as a therapy. Complement Ther Med. 2020; 48 : 102242. PubMed Abstract | Publisher Full Text 57. Nduma BN, Mofor KA, Tatang J, et al. : The use of cannabinoids in the treatment of Inflammatory Bowel Disease (IBD): a review of the literature. Cureus. 2023; 15 (3): e36148. PubMed Abstract | Publisher Full Text | Free Full Text 58. Vinci A, Ingravalle F, Bardhi D, et al. : Cannabinoid therapeutic effects in Inflammatory Bowel Diseases: a systematic review and meta-analysis of Randomized Controlled Trials. Biomedicines. 2022; 10 (10): 2439. PubMed Abstract | Publisher Full Text | Free Full Text 59. Dworkin RH, Turk DC, Wyrwich KW, et al. : Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008; 9 (2): 105–121. PubMed Abstract | Publisher Full Text 60. Page MJ, McKenzie JE, Bossuyt PM, et al. : The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021; 18 (3): e1003583. PubMed Abstract | Publisher Full Text | Free Full Text 61. Sturm A, Maaser C, Calabrese E, et al. : ECCO-ESGAR guideline for diagnostic assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019; 13 (3): 273–284. PubMed Abstract | Publisher Full Text 62. Zorzela L, Loke YK, Ioannidis JP, et al. : PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016; 352 : i157. PubMed Abstract | Publisher Full Text 63. Sterne JAC, Savović J, Page MJ, et al. : RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366 : l4898. PubMed Abstract | Publisher Full Text 64. Higgins J, Savović J, Page MJ, et al. : Chapter 8: assessing risk of bias in a randomized trial. In: Cochrane Handbook for Systematic Reviews of Interventions . T.J. Higgins JP, Chandler J, Cumpston M, Li T, Page MJ, Welch VA,, Editor. Cochrane, 2023. 65. Erskine A: Template for intervention review (Protocol). Cochrane Database of Systematic Reviews. 66. Dechartres A, Trinquart L, Boutron I, et al. : Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ. 2013; 346 : f2304. PubMed Abstract | Publisher Full Text | Free Full Text 67. GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime). 68. Guyatt GH, Oxman AD, Vist GE, et al. : GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336 (7650): 924–6. PubMed Abstract | Publisher Full Text | Free Full Text 69. Lane R: Systematic review of Endocannabinoid System modulation for Visceral Abdominal Pain in Inflammatory Bowel Disease and Irritable Bowel Syndrome. [Dataset] OSF, 2024. http://www.doi.org/10.17605/OSF.IO/PJTVU Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 13 Mar 2025 ADD YOUR COMMENT Comment Author details Author details 1 Pharmacology and Therapeutics, School of Medicine, University of Galway, Galway, Ireland 2 Centre for Pain Research, University of Galway, Galway, Ireland 3 Galway Neuroscience Centre, University of Galway, Galway, Ireland 4 Gastroenterology, Galway University Hospital, Galway, Ireland 5 School of Psychology, University of Galway, Galway, Ireland 6 Anatomy and Neuroscience, University College Cork and APC Microbiome Ireland, Cork, Ireland Rebecca M. Lane Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation Laurence J. Egan Roles: Supervision, Writing – Review & Editing Brian E. McGuire Roles: Supervision, Writing – Review & Editing Declan P. McKernan Roles: Supervision, Writing – Review & Editing Siobhain M. O'Mahony Roles: Writing – Review & Editing David P. Finn Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing Competing interests D.P. Finn reports grant funding from B. Braun Ltd, outside the submitted work. Grant information This work is funded by Taighde Éireann –Research Ireland [GOIPG/2024/4981]. This work was also supported by the University of Galway Hardiman Research Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article Versions (2) version 2 Revised Published: 23 Jul 2025, 8:40 https://doi.org/10.12688/hrbopenres.14082.2 version 1 Published: 13 Mar 2025, 8:40 https://doi.org/10.12688/hrbopenres.14082.1 Copyright © 2025 Lane RM et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics VIEWS $counts.viewCount downloads Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Lane RM, Egan LJ, McGuire BE et al. Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] . HRB Open Res 2025, 8 :40 ( https://doi.org/10.12688/hrbopenres.14082.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 2 VERSION 2 PUBLISHED 23 Jul 2025 Revised Views 0 Cite How to cite this report: Erridge S. Reviewer Report For: Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] . HRB Open Res 2025, 8 :40 ( https://doi.org/10.21956/hrbopenres.15616.r48535 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-40/v2#referee-response-48535 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 23 Aug 2025 Simon Erridge , Imperial College London, London, England, UK Approved VIEWS 0 https://doi.org/10.21956/hrbopenres.15616.r48535 Happy with the changes made - ... Continue reading READ ALL Happy with the changes made - thank you. I approve indexing the manuscript. Competing Interests: Employee of Curaleaf Clinic Reviewer Expertise: Medical cannabis and pain I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Erridge S. Reviewer Report For: Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] . HRB Open Res 2025, 8 :40 ( https://doi.org/10.21956/hrbopenres.15616.r48535 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-40/v2#referee-response-48535 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Version 1 VERSION 1 PUBLISHED 13 Mar 2025 Views 0 Cite How to cite this report: Collins CB. Reviewer Report For: Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] . HRB Open Res 2025, 8 :40 ( https://doi.org/10.21956/hrbopenres.15469.r46403 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-40/v1#referee-response-46403 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 26 Mar 2025 Colm B Collins , University College Dublin, Dublin, Leinster, Ireland Approved VIEWS 0 https://doi.org/10.21956/hrbopenres.15469.r46403 This represents a really interesting study which will have considerable implications for the field going forward. This is a well-written protocol which highlights the considerable cross-disciplinary expertise that the group can bring to bear. I have only ... Continue reading READ ALL This represents a really interesting study which will have considerable implications for the field going forward. This is a well-written protocol which highlights the considerable cross-disciplinary expertise that the group can bring to bear. I have only a few minor suggestions. The abstract is already acronym-heavy, so I would consider removing the reference to IMMPACT without defining the initiative for improved accessibility. For discussion of endocannabinoid tone in IBD patients, consider adding a reference to Leinwand et al, J Crohns Colitis. 2017 Oct 27;11(11):1369-1380 (for receptor expression in CD patients) and Matalon et al., 2021 Front. Endocrinol (for serum endocannabinoid expression in UC/CD). Consider including a reference to the chronic nature of visceral pain experienced by individuals with these diseases along with the risk of dependence and opioid-induced hyperalgesia as additional reasons for needing an alternative approach to pain management in these conditions. Will indeterminate colitis or infectious colitis/gastroenteritis be included within the scope of this study, given that the former is often included as part of a catch-all of IBD patients, and the latter is the number one cause of visceral pain? Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Yes Are the datasets clearly presented in a useable and accessible format? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: My research lab is focused on the role of cannabinoid in the regulation intestinal inflammation in IBD. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Collins CB. Reviewer Report For: Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] . HRB Open Res 2025, 8 :40 ( https://doi.org/10.21956/hrbopenres.15469.r46403 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-40/v1#referee-response-46403 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 09 Sep 2025 David Finn , Pharmacology and Therapeutics, School of Medicine, University of Galway, Galway, Ireland 09 Sep 2025 Author Response Reviewer’s comments: The abstract is already acronym-heavy, so I would consider removing the reference to IMMPACT without defining the initiative for improved accessibility. Response: We have removed ‘as ... Continue reading Reviewer’s comments: The abstract is already acronym-heavy, so I would consider removing the reference to IMMPACT without defining the initiative for improved accessibility. Response: We have removed ‘as defined by IMMPACT’ in the revised version. Manuscript page: 2 Paragraph: 1 Line number: 2 Reviewer’s comment: Consider including a reference to the chronic nature of visceral pain experienced by individuals with these diseases along with the risk of dependence and opioid-induced hyperalgesia as additional reasons for needing an alternative approach to pain management in these conditions. Response: We have revised the text as follows in the revised version to include these points. “Adverse effects of commonly used analgesics (e.g., aspirin and other non-steroidal anti-inflammatory drugs, opioids) on the gastrointestinal tract are of particular concern in these patient populations. Furthermore, chronic use of some analgesics, such as opioids, could lead to dependence and opioid-induced hyperalgesia. “ We have also included an additional reference to support this statement: We have also added this reference: Ballantyne, Jane C.a,b,*; LaForge, Steven K.c. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129(3):p 235-255, June 2007. | DOI: 10.1016/j.pain.2007.03.028 Page: 3 Paragraph: 1 Line: 14 Reviewer’s comment: For discussion of endocannabinoid tone in IBD patients, consider adding a reference to Leinwand et al, J Crohns Colitis. 2017 Oct 27;11(11):1369-1380 (for receptor expression in CD patients) and Matalon et al., 2021 Front. Endocrinol (for serum endocannabinoid expression in UC/CD). Response: Thank you for these suggestions, we have added these references. Page: 3 Paragraph: 2 Line: 22 & 24 Reviewer’s comment : Will indeterminate colitis or infectious colitis/gastroenteritis be included within the scope of this study, given that the former is often included as part of a catch-all of IBD patients, and the latter is the number one cause of visceral pain? Response: Thank you for this suggestion. We will include indeterminate colitis as a subtype of IBD, but not infectious colitis/gastroenteritis as we consider these outside the scope of this review. The text has been changed to reflect this in the revised version: “IBD: Crohn’s disease [CD], ulcerative colitis [UC], indeterminate colitis [IC])” Page: 5 Paragraph: 5 Line: 15 Reviewer’s comments: The abstract is already acronym-heavy, so I would consider removing the reference to IMMPACT without defining the initiative for improved accessibility. Response: We have removed ‘as defined by IMMPACT’ in the revised version. Manuscript page: 2 Paragraph: 1 Line number: 2 Reviewer’s comment: Consider including a reference to the chronic nature of visceral pain experienced by individuals with these diseases along with the risk of dependence and opioid-induced hyperalgesia as additional reasons for needing an alternative approach to pain management in these conditions. Response: We have revised the text as follows in the revised version to include these points. “Adverse effects of commonly used analgesics (e.g., aspirin and other non-steroidal anti-inflammatory drugs, opioids) on the gastrointestinal tract are of particular concern in these patient populations. Furthermore, chronic use of some analgesics, such as opioids, could lead to dependence and opioid-induced hyperalgesia. “ We have also included an additional reference to support this statement: We have also added this reference: Ballantyne, Jane C.a,b,*; LaForge, Steven K.c. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129(3):p 235-255, June 2007. | DOI: 10.1016/j.pain.2007.03.028 Page: 3 Paragraph: 1 Line: 14 Reviewer’s comment: For discussion of endocannabinoid tone in IBD patients, consider adding a reference to Leinwand et al, J Crohns Colitis. 2017 Oct 27;11(11):1369-1380 (for receptor expression in CD patients) and Matalon et al., 2021 Front. Endocrinol (for serum endocannabinoid expression in UC/CD). Response: Thank you for these suggestions, we have added these references. Page: 3 Paragraph: 2 Line: 22 & 24 Reviewer’s comment : Will indeterminate colitis or infectious colitis/gastroenteritis be included within the scope of this study, given that the former is often included as part of a catch-all of IBD patients, and the latter is the number one cause of visceral pain? Response: Thank you for this suggestion. We will include indeterminate colitis as a subtype of IBD, but not infectious colitis/gastroenteritis as we consider these outside the scope of this review. The text has been changed to reflect this in the revised version: “IBD: Crohn’s disease [CD], ulcerative colitis [UC], indeterminate colitis [IC])” Page: 5 Paragraph: 5 Line: 15 Competing Interests: None Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 09 Sep 2025 David Finn , Pharmacology and Therapeutics, School of Medicine, University of Galway, Galway, Ireland 09 Sep 2025 Author Response Reviewer’s comments: The abstract is already acronym-heavy, so I would consider removing the reference to IMMPACT without defining the initiative for improved accessibility. Response: We have removed ‘as ... Continue reading Reviewer’s comments: The abstract is already acronym-heavy, so I would consider removing the reference to IMMPACT without defining the initiative for improved accessibility. Response: We have removed ‘as defined by IMMPACT’ in the revised version. Manuscript page: 2 Paragraph: 1 Line number: 2 Reviewer’s comment: Consider including a reference to the chronic nature of visceral pain experienced by individuals with these diseases along with the risk of dependence and opioid-induced hyperalgesia as additional reasons for needing an alternative approach to pain management in these conditions. Response: We have revised the text as follows in the revised version to include these points. “Adverse effects of commonly used analgesics (e.g., aspirin and other non-steroidal anti-inflammatory drugs, opioids) on the gastrointestinal tract are of particular concern in these patient populations. Furthermore, chronic use of some analgesics, such as opioids, could lead to dependence and opioid-induced hyperalgesia. “ We have also included an additional reference to support this statement: We have also added this reference: Ballantyne, Jane C.a,b,*; LaForge, Steven K.c. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129(3):p 235-255, June 2007. | DOI: 10.1016/j.pain.2007.03.028 Page: 3 Paragraph: 1 Line: 14 Reviewer’s comment: For discussion of endocannabinoid tone in IBD patients, consider adding a reference to Leinwand et al, J Crohns Colitis. 2017 Oct 27;11(11):1369-1380 (for receptor expression in CD patients) and Matalon et al., 2021 Front. Endocrinol (for serum endocannabinoid expression in UC/CD). Response: Thank you for these suggestions, we have added these references. Page: 3 Paragraph: 2 Line: 22 & 24 Reviewer’s comment : Will indeterminate colitis or infectious colitis/gastroenteritis be included within the scope of this study, given that the former is often included as part of a catch-all of IBD patients, and the latter is the number one cause of visceral pain? Response: Thank you for this suggestion. We will include indeterminate colitis as a subtype of IBD, but not infectious colitis/gastroenteritis as we consider these outside the scope of this review. The text has been changed to reflect this in the revised version: “IBD: Crohn’s disease [CD], ulcerative colitis [UC], indeterminate colitis [IC])” Page: 5 Paragraph: 5 Line: 15 Reviewer’s comments: The abstract is already acronym-heavy, so I would consider removing the reference to IMMPACT without defining the initiative for improved accessibility. Response: We have removed ‘as defined by IMMPACT’ in the revised version. Manuscript page: 2 Paragraph: 1 Line number: 2 Reviewer’s comment: Consider including a reference to the chronic nature of visceral pain experienced by individuals with these diseases along with the risk of dependence and opioid-induced hyperalgesia as additional reasons for needing an alternative approach to pain management in these conditions. Response: We have revised the text as follows in the revised version to include these points. “Adverse effects of commonly used analgesics (e.g., aspirin and other non-steroidal anti-inflammatory drugs, opioids) on the gastrointestinal tract are of particular concern in these patient populations. Furthermore, chronic use of some analgesics, such as opioids, could lead to dependence and opioid-induced hyperalgesia. “ We have also included an additional reference to support this statement: We have also added this reference: Ballantyne, Jane C.a,b,*; LaForge, Steven K.c. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129(3):p 235-255, June 2007. | DOI: 10.1016/j.pain.2007.03.028 Page: 3 Paragraph: 1 Line: 14 Reviewer’s comment: For discussion of endocannabinoid tone in IBD patients, consider adding a reference to Leinwand et al, J Crohns Colitis. 2017 Oct 27;11(11):1369-1380 (for receptor expression in CD patients) and Matalon et al., 2021 Front. Endocrinol (for serum endocannabinoid expression in UC/CD). Response: Thank you for these suggestions, we have added these references. Page: 3 Paragraph: 2 Line: 22 & 24 Reviewer’s comment : Will indeterminate colitis or infectious colitis/gastroenteritis be included within the scope of this study, given that the former is often included as part of a catch-all of IBD patients, and the latter is the number one cause of visceral pain? Response: Thank you for this suggestion. We will include indeterminate colitis as a subtype of IBD, but not infectious colitis/gastroenteritis as we consider these outside the scope of this review. The text has been changed to reflect this in the revised version: “IBD: Crohn’s disease [CD], ulcerative colitis [UC], indeterminate colitis [IC])” Page: 5 Paragraph: 5 Line: 15 Competing Interests: None Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Erridge S. Reviewer Report For: Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] . HRB Open Res 2025, 8 :40 ( https://doi.org/10.21956/hrbopenres.15469.r46401 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-40/v1#referee-response-46401 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 22 Mar 2025 Simon Erridge , Imperial College London, London, England, UK Approved with Reservations VIEWS 0 https://doi.org/10.21956/hrbopenres.15469.r46401 This is a nice piece of work which is well written - well done. A few suggestions: Abstract 1. For this sentence in the abstract ((a) at least a 30% reduction and (b) at least ... Continue reading READ ALL This is a nice piece of work which is well written - well done. A few suggestions: Abstract 1. For this sentence in the abstract ((a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity as defined by IMMPACT) I would drop the part which says 'as defined by IMMPACT'. I understand what you mean in terms of their clinical relevance being defined by IMMPACT but the 30/50% reduction itself is not being defined by IMMPACT. Introduction 1. As per above in your objectives just a semantic point - I would edit your objectives. The primary outcome measures of 30% / 50% reduction are not defined by IMMPACT, rather the clinical significance of these cut offs are defined by IMMPACT, so would just tweak how you have worded this. Methods 1. I am assuming you are including these, but it would be helpful to define additional study parameters by which you will consider their inclusion i.e. number of participants, length of follow up etc. 2. It would be good to define what you will include as an other ECS modulator. Are you limiting this to PEA and similar, or are you considering other medications that may impact the endocannabinoid system. 3. Will you include studies which use cannabis taken recreationally? I imagine there aren't many/any, but again good to define this before you start the review. Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Partly Are the datasets clearly presented in a useable and accessible format? Not applicable Competing Interests: Employed by Curaleaf Clinic, UK Reviewer Expertise: Medical cannabis and pain I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Erridge S. Reviewer Report For: Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] . HRB Open Res 2025, 8 :40 ( https://doi.org/10.21956/hrbopenres.15469.r46401 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-40/v1#referee-response-46401 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 09 Sep 2025 David Finn , Pharmacology and Therapeutics, School of Medicine, University of Galway, Galway, Ireland 09 Sep 2025 Author Response Reviewer’s comments: For this sentence in the abstract ((a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity as defined by IMMPACT) I would ... Continue reading Reviewer’s comments: For this sentence in the abstract ((a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity as defined by IMMPACT) I would drop the part which says 'as defined by IMMPACT'. I understand what you mean in terms of their clinical relevance being defined by IMMPACT but the 30/50% reduction itself is not being defined by IMMPACT. Response: We have removed ‘as defined by IMMPACT’ in the revised version. Manuscript page: 2 Paragraph: 1 Line number: 2 Reviewer’s comment : As per above in your objectives just a semantic point - I would edit your objectives. The primary outcome measures of 30% / 50% reduction are not defined by IMMPACT, rather the clinical significance of these cut offs are defined by IMMPACT, so would just tweak how you have worded this. Response: We have changed the text to the following in the revised version: “The primary outcome measures will be the proportion of people with (a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity (measured using a 0–10 numerical rating scale). We have chosen these specific percentage reductions as their clinical significance is supported by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)”. We have also reflected this change in the primary outcomes section. Page: 3 Paragraph: 6 Line: 8 Reviewer’s comment: I am assuming you are including these, but it would be helpful to define additional study parameters by which you will consider their inclusion i.e. number of participants, length of follow up etc. Response: As we are not anticipating a large number of studies, we do not want to limit our inclusion by number of participants, or length of follow up. We will report on all studies that fit our criteria, but we will only include studies with greater than 30 participants post-treatment per group in the meta-analysis as stated in the synthesis methods section. If there is a clear division in the included studies with regards length of follow up, we will acknowledge this in our discussion and interrogate it in our analysis. The text has been updated to reflect this in the revised version: “Study characteristics: aims, design, participants enrolled per arm, enrolment method, inclusion/exclusion criteria, length of follow up (including potential sources of bias). “These tables will include participant characteristics, post-treatment N, length of follow up, and descriptions of interventions, comparators, duration of treatment, and outcome measures of interest for this review, including adverse event description and frequency. “If the data allows, we will perform the following subgroup analysis: i Classification of IBS: IBS-C, IBS-D, IBS-M ii Diagnostic criteria of IBS: ROME III, ROME IV iii Classification of IBD: CD, UC, IC iv Intervention type v Comparator type vi length of follow up vii treatment duration” Page: 5 Paragraph: 5 Line: 8 Page: 6 Paragraph: 2 & 3 Line: 4 & 24 Reviewer’s comment: Will you include studies which use cannabis taken recreationally? I imagine there aren't many/any, but again good to define this before you start the review. Response: We will limit our scope to RCTs, which therefore will exclude these studies of recreational use. Reviewer’s comment : It would be good to define what you will include as an other ECS modulator. Are you limiting this to PEA and similar, or are you considering other medications that may impact the endocannabinoid system. Response: We are limiting it to medications that have a targeted effect on the ECS, rather than any medications that can indirectly affect the ECS. We have revised the text under interventions and comparisons in the revised version to “Other ECS modulators (e.g., cannabinoid receptor antagonists; ECS enzyme inhibitors, modulators or substrates).” Page 4: Paragraph: 4 Line: 6 Reviewer’s comments: For this sentence in the abstract ((a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity as defined by IMMPACT) I would drop the part which says 'as defined by IMMPACT'. I understand what you mean in terms of their clinical relevance being defined by IMMPACT but the 30/50% reduction itself is not being defined by IMMPACT. Response: We have removed ‘as defined by IMMPACT’ in the revised version. Manuscript page: 2 Paragraph: 1 Line number: 2 Reviewer’s comment : As per above in your objectives just a semantic point - I would edit your objectives. The primary outcome measures of 30% / 50% reduction are not defined by IMMPACT, rather the clinical significance of these cut offs are defined by IMMPACT, so would just tweak how you have worded this. Response: We have changed the text to the following in the revised version: “The primary outcome measures will be the proportion of people with (a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity (measured using a 0–10 numerical rating scale). We have chosen these specific percentage reductions as their clinical significance is supported by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)”. We have also reflected this change in the primary outcomes section. Page: 3 Paragraph: 6 Line: 8 Reviewer’s comment: I am assuming you are including these, but it would be helpful to define additional study parameters by which you will consider their inclusion i.e. number of participants, length of follow up etc. Response: As we are not anticipating a large number of studies, we do not want to limit our inclusion by number of participants, or length of follow up. We will report on all studies that fit our criteria, but we will only include studies with greater than 30 participants post-treatment per group in the meta-analysis as stated in the synthesis methods section. If there is a clear division in the included studies with regards length of follow up, we will acknowledge this in our discussion and interrogate it in our analysis. The text has been updated to reflect this in the revised version: “Study characteristics: aims, design, participants enrolled per arm, enrolment method, inclusion/exclusion criteria, length of follow up (including potential sources of bias). “These tables will include participant characteristics, post-treatment N, length of follow up, and descriptions of interventions, comparators, duration of treatment, and outcome measures of interest for this review, including adverse event description and frequency. “If the data allows, we will perform the following subgroup analysis: i Classification of IBS: IBS-C, IBS-D, IBS-M ii Diagnostic criteria of IBS: ROME III, ROME IV iii Classification of IBD: CD, UC, IC iv Intervention type v Comparator type vi length of follow up vii treatment duration” Page: 5 Paragraph: 5 Line: 8 Page: 6 Paragraph: 2 & 3 Line: 4 & 24 Reviewer’s comment: Will you include studies which use cannabis taken recreationally? I imagine there aren't many/any, but again good to define this before you start the review. Response: We will limit our scope to RCTs, which therefore will exclude these studies of recreational use. Reviewer’s comment : It would be good to define what you will include as an other ECS modulator. Are you limiting this to PEA and similar, or are you considering other medications that may impact the endocannabinoid system. Response: We are limiting it to medications that have a targeted effect on the ECS, rather than any medications that can indirectly affect the ECS. We have revised the text under interventions and comparisons in the revised version to “Other ECS modulators (e.g., cannabinoid receptor antagonists; ECS enzyme inhibitors, modulators or substrates).” Page 4: Paragraph: 4 Line: 6 Competing Interests: None Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 09 Sep 2025 David Finn , Pharmacology and Therapeutics, School of Medicine, University of Galway, Galway, Ireland 09 Sep 2025 Author Response Reviewer’s comments: For this sentence in the abstract ((a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity as defined by IMMPACT) I would ... Continue reading Reviewer’s comments: For this sentence in the abstract ((a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity as defined by IMMPACT) I would drop the part which says 'as defined by IMMPACT'. I understand what you mean in terms of their clinical relevance being defined by IMMPACT but the 30/50% reduction itself is not being defined by IMMPACT. Response: We have removed ‘as defined by IMMPACT’ in the revised version. Manuscript page: 2 Paragraph: 1 Line number: 2 Reviewer’s comment : As per above in your objectives just a semantic point - I would edit your objectives. The primary outcome measures of 30% / 50% reduction are not defined by IMMPACT, rather the clinical significance of these cut offs are defined by IMMPACT, so would just tweak how you have worded this. Response: We have changed the text to the following in the revised version: “The primary outcome measures will be the proportion of people with (a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity (measured using a 0–10 numerical rating scale). We have chosen these specific percentage reductions as their clinical significance is supported by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)”. We have also reflected this change in the primary outcomes section. Page: 3 Paragraph: 6 Line: 8 Reviewer’s comment: I am assuming you are including these, but it would be helpful to define additional study parameters by which you will consider their inclusion i.e. number of participants, length of follow up etc. Response: As we are not anticipating a large number of studies, we do not want to limit our inclusion by number of participants, or length of follow up. We will report on all studies that fit our criteria, but we will only include studies with greater than 30 participants post-treatment per group in the meta-analysis as stated in the synthesis methods section. If there is a clear division in the included studies with regards length of follow up, we will acknowledge this in our discussion and interrogate it in our analysis. The text has been updated to reflect this in the revised version: “Study characteristics: aims, design, participants enrolled per arm, enrolment method, inclusion/exclusion criteria, length of follow up (including potential sources of bias). “These tables will include participant characteristics, post-treatment N, length of follow up, and descriptions of interventions, comparators, duration of treatment, and outcome measures of interest for this review, including adverse event description and frequency. “If the data allows, we will perform the following subgroup analysis: i Classification of IBS: IBS-C, IBS-D, IBS-M ii Diagnostic criteria of IBS: ROME III, ROME IV iii Classification of IBD: CD, UC, IC iv Intervention type v Comparator type vi length of follow up vii treatment duration” Page: 5 Paragraph: 5 Line: 8 Page: 6 Paragraph: 2 & 3 Line: 4 & 24 Reviewer’s comment: Will you include studies which use cannabis taken recreationally? I imagine there aren't many/any, but again good to define this before you start the review. Response: We will limit our scope to RCTs, which therefore will exclude these studies of recreational use. Reviewer’s comment : It would be good to define what you will include as an other ECS modulator. Are you limiting this to PEA and similar, or are you considering other medications that may impact the endocannabinoid system. Response: We are limiting it to medications that have a targeted effect on the ECS, rather than any medications that can indirectly affect the ECS. We have revised the text under interventions and comparisons in the revised version to “Other ECS modulators (e.g., cannabinoid receptor antagonists; ECS enzyme inhibitors, modulators or substrates).” Page 4: Paragraph: 4 Line: 6 Reviewer’s comments: For this sentence in the abstract ((a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity as defined by IMMPACT) I would drop the part which says 'as defined by IMMPACT'. I understand what you mean in terms of their clinical relevance being defined by IMMPACT but the 30/50% reduction itself is not being defined by IMMPACT. Response: We have removed ‘as defined by IMMPACT’ in the revised version. Manuscript page: 2 Paragraph: 1 Line number: 2 Reviewer’s comment : As per above in your objectives just a semantic point - I would edit your objectives. The primary outcome measures of 30% / 50% reduction are not defined by IMMPACT, rather the clinical significance of these cut offs are defined by IMMPACT, so would just tweak how you have worded this. Response: We have changed the text to the following in the revised version: “The primary outcome measures will be the proportion of people with (a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity (measured using a 0–10 numerical rating scale). We have chosen these specific percentage reductions as their clinical significance is supported by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)”. We have also reflected this change in the primary outcomes section. Page: 3 Paragraph: 6 Line: 8 Reviewer’s comment: I am assuming you are including these, but it would be helpful to define additional study parameters by which you will consider their inclusion i.e. number of participants, length of follow up etc. Response: As we are not anticipating a large number of studies, we do not want to limit our inclusion by number of participants, or length of follow up. We will report on all studies that fit our criteria, but we will only include studies with greater than 30 participants post-treatment per group in the meta-analysis as stated in the synthesis methods section. If there is a clear division in the included studies with regards length of follow up, we will acknowledge this in our discussion and interrogate it in our analysis. The text has been updated to reflect this in the revised version: “Study characteristics: aims, design, participants enrolled per arm, enrolment method, inclusion/exclusion criteria, length of follow up (including potential sources of bias). “These tables will include participant characteristics, post-treatment N, length of follow up, and descriptions of interventions, comparators, duration of treatment, and outcome measures of interest for this review, including adverse event description and frequency. “If the data allows, we will perform the following subgroup analysis: i Classification of IBS: IBS-C, IBS-D, IBS-M ii Diagnostic criteria of IBS: ROME III, ROME IV iii Classification of IBD: CD, UC, IC iv Intervention type v Comparator type vi length of follow up vii treatment duration” Page: 5 Paragraph: 5 Line: 8 Page: 6 Paragraph: 2 & 3 Line: 4 & 24 Reviewer’s comment: Will you include studies which use cannabis taken recreationally? I imagine there aren't many/any, but again good to define this before you start the review. Response: We will limit our scope to RCTs, which therefore will exclude these studies of recreational use. Reviewer’s comment : It would be good to define what you will include as an other ECS modulator. Are you limiting this to PEA and similar, or are you considering other medications that may impact the endocannabinoid system. Response: We are limiting it to medications that have a targeted effect on the ECS, rather than any medications that can indirectly affect the ECS. We have revised the text under interventions and comparisons in the revised version to “Other ECS modulators (e.g., cannabinoid receptor antagonists; ECS enzyme inhibitors, modulators or substrates).” Page 4: Paragraph: 4 Line: 6 Competing Interests: None Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 13 Mar 2025 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 Version 2 (revision) 23 Jul 25 read Version 1 13 Mar 25 read read Simon Erridge , Imperial College London, London, UK Colm B Collins , University College Dublin, Dublin, Ireland Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Erridge S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 23 Aug 2025 | for Version 2 Simon Erridge , Imperial College London, London, England, UK 0 Views copyright © 2025 Erridge S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Happy with the changes made - thank you. I approve indexing the manuscript. Competing Interests Employee of Curaleaf Clinic Reviewer Expertise Medical cannabis and pain I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Erridge S. Peer Review Report For: Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] . HRB Open Res 2025, 8 :40 ( https://doi.org/10.21956/hrbopenres.15616.r48535) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://hrbopenresearch.org/articles/8-40/v2#referee-response-48535 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Collins C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 26 Mar 2025 | for Version 1 Colm B Collins , University College Dublin, Dublin, Leinster, Ireland 0 Views copyright © 2025 Collins C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This represents a really interesting study which will have considerable implications for the field going forward. This is a well-written protocol which highlights the considerable cross-disciplinary expertise that the group can bring to bear. I have only a few minor suggestions. The abstract is already acronym-heavy, so I would consider removing the reference to IMMPACT without defining the initiative for improved accessibility. For discussion of endocannabinoid tone in IBD patients, consider adding a reference to Leinwand et al, J Crohns Colitis. 2017 Oct 27;11(11):1369-1380 (for receptor expression in CD patients) and Matalon et al., 2021 Front. Endocrinol (for serum endocannabinoid expression in UC/CD). Consider including a reference to the chronic nature of visceral pain experienced by individuals with these diseases along with the risk of dependence and opioid-induced hyperalgesia as additional reasons for needing an alternative approach to pain management in these conditions. Will indeterminate colitis or infectious colitis/gastroenteritis be included within the scope of this study, given that the former is often included as part of a catch-all of IBD patients, and the latter is the number one cause of visceral pain? Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Yes Are the datasets clearly presented in a useable and accessible format? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise My research lab is focused on the role of cannabinoid in the regulation intestinal inflammation in IBD. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 09 Sep 2025 David Finn, Pharmacology and Therapeutics, School of Medicine, University of Galway, Galway, Ireland Reviewer’s comments: The abstract is already acronym-heavy, so I would consider removing the reference to IMMPACT without defining the initiative for improved accessibility. Response: We have removed ‘as defined by IMMPACT’ in the revised version. Manuscript page: 2 Paragraph: 1 Line number: 2 Reviewer’s comment: Consider including a reference to the chronic nature of visceral pain experienced by individuals with these diseases along with the risk of dependence and opioid-induced hyperalgesia as additional reasons for needing an alternative approach to pain management in these conditions. Response: We have revised the text as follows in the revised version to include these points. “Adverse effects of commonly used analgesics (e.g., aspirin and other non-steroidal anti-inflammatory drugs, opioids) on the gastrointestinal tract are of particular concern in these patient populations. Furthermore, chronic use of some analgesics, such as opioids, could lead to dependence and opioid-induced hyperalgesia. “ We have also included an additional reference to support this statement: We have also added this reference: Ballantyne, Jane C.a,b,*; LaForge, Steven K.c. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129(3):p 235-255, June 2007. | DOI: 10.1016/j.pain.2007.03.028 Page: 3 Paragraph: 1 Line: 14 Reviewer’s comment: For discussion of endocannabinoid tone in IBD patients, consider adding a reference to Leinwand et al, J Crohns Colitis. 2017 Oct 27;11(11):1369-1380 (for receptor expression in CD patients) and Matalon et al., 2021 Front. Endocrinol (for serum endocannabinoid expression in UC/CD). Response: Thank you for these suggestions, we have added these references. Page: 3 Paragraph: 2 Line: 22 & 24 Reviewer’s comment : Will indeterminate colitis or infectious colitis/gastroenteritis be included within the scope of this study, given that the former is often included as part of a catch-all of IBD patients, and the latter is the number one cause of visceral pain? Response: Thank you for this suggestion. We will include indeterminate colitis as a subtype of IBD, but not infectious colitis/gastroenteritis as we consider these outside the scope of this review. The text has been changed to reflect this in the revised version: “IBD: Crohn’s disease [CD], ulcerative colitis [UC], indeterminate colitis [IC])” Page: 5 Paragraph: 5 Line: 15 View more View less Competing Interests None reply Respond Report a concern Collins CB. Peer Review Report For: Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] . HRB Open Res 2025, 8 :40 ( https://doi.org/10.21956/hrbopenres.15469.r46403) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://hrbopenresearch.org/articles/8-40/v1#referee-response-46403 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Erridge S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 22 Mar 2025 | for Version 1 Simon Erridge , Imperial College London, London, England, UK 0 Views copyright © 2025 Erridge S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This is a nice piece of work which is well written - well done. A few suggestions: Abstract 1. For this sentence in the abstract ((a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity as defined by IMMPACT) I would drop the part which says 'as defined by IMMPACT'. I understand what you mean in terms of their clinical relevance being defined by IMMPACT but the 30/50% reduction itself is not being defined by IMMPACT. Introduction 1. As per above in your objectives just a semantic point - I would edit your objectives. The primary outcome measures of 30% / 50% reduction are not defined by IMMPACT, rather the clinical significance of these cut offs are defined by IMMPACT, so would just tweak how you have worded this. Methods 1. I am assuming you are including these, but it would be helpful to define additional study parameters by which you will consider their inclusion i.e. number of participants, length of follow up etc. 2. It would be good to define what you will include as an other ECS modulator. Are you limiting this to PEA and similar, or are you considering other medications that may impact the endocannabinoid system. 3. Will you include studies which use cannabis taken recreationally? I imagine there aren't many/any, but again good to define this before you start the review. Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Partly Are the datasets clearly presented in a useable and accessible format? Not applicable Competing Interests Employed by Curaleaf Clinic, UK Reviewer Expertise Medical cannabis and pain I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 09 Sep 2025 David Finn, Pharmacology and Therapeutics, School of Medicine, University of Galway, Galway, Ireland Reviewer’s comments: For this sentence in the abstract ((a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity as defined by IMMPACT) I would drop the part which says 'as defined by IMMPACT'. I understand what you mean in terms of their clinical relevance being defined by IMMPACT but the 30/50% reduction itself is not being defined by IMMPACT. Response: We have removed ‘as defined by IMMPACT’ in the revised version. Manuscript page: 2 Paragraph: 1 Line number: 2 Reviewer’s comment : As per above in your objectives just a semantic point - I would edit your objectives. The primary outcome measures of 30% / 50% reduction are not defined by IMMPACT, rather the clinical significance of these cut offs are defined by IMMPACT, so would just tweak how you have worded this. Response: We have changed the text to the following in the revised version: “The primary outcome measures will be the proportion of people with (a) at least a 30% reduction and (b) at least a 50% reduction in pain intensity (measured using a 0–10 numerical rating scale). We have chosen these specific percentage reductions as their clinical significance is supported by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)”. We have also reflected this change in the primary outcomes section. Page: 3 Paragraph: 6 Line: 8 Reviewer’s comment: I am assuming you are including these, but it would be helpful to define additional study parameters by which you will consider their inclusion i.e. number of participants, length of follow up etc. Response: As we are not anticipating a large number of studies, we do not want to limit our inclusion by number of participants, or length of follow up. We will report on all studies that fit our criteria, but we will only include studies with greater than 30 participants post-treatment per group in the meta-analysis as stated in the synthesis methods section. If there is a clear division in the included studies with regards length of follow up, we will acknowledge this in our discussion and interrogate it in our analysis. The text has been updated to reflect this in the revised version: “Study characteristics: aims, design, participants enrolled per arm, enrolment method, inclusion/exclusion criteria, length of follow up (including potential sources of bias). “These tables will include participant characteristics, post-treatment N, length of follow up, and descriptions of interventions, comparators, duration of treatment, and outcome measures of interest for this review, including adverse event description and frequency. “If the data allows, we will perform the following subgroup analysis: i Classification of IBS: IBS-C, IBS-D, IBS-M ii Diagnostic criteria of IBS: ROME III, ROME IV iii Classification of IBD: CD, UC, IC iv Intervention type v Comparator type vi length of follow up vii treatment duration” Page: 5 Paragraph: 5 Line: 8 Page: 6 Paragraph: 2 & 3 Line: 4 & 24 Reviewer’s comment: Will you include studies which use cannabis taken recreationally? I imagine there aren't many/any, but again good to define this before you start the review. Response: We will limit our scope to RCTs, which therefore will exclude these studies of recreational use. Reviewer’s comment : It would be good to define what you will include as an other ECS modulator. Are you limiting this to PEA and similar, or are you considering other medications that may impact the endocannabinoid system. Response: We are limiting it to medications that have a targeted effect on the ECS, rather than any medications that can indirectly affect the ECS. We have revised the text under interventions and comparisons in the revised version to “Other ECS modulators (e.g., cannabinoid receptor antagonists; ECS enzyme inhibitors, modulators or substrates).” Page 4: Paragraph: 4 Line: 6 View more View less Competing Interests None reply Respond Report a concern Erridge S. Peer Review Report For: Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis [version 2; peer review: 2 approved] . HRB Open Res 2025, 8 :40 ( https://doi.org/10.21956/hrbopenres.15469.r46401) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://hrbopenresearch.org/articles/8-40/v1#referee-response-46401 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with HRB Open Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Endocannabinoid system modulation for visceral...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://hrbopenresearch.org/articles/8-40/v2" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://hrbopenresearch.org/articles/8-40/v2&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://hrbopenresearch.org/articles/8-40/v2" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Lane RM et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://hrbopenresearch.org/articles/8-40/v2/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://hrbopenresearch.org/articles/8-40", templates : { twitter : "Endocannabinoid system modulation for visceral abdominal pain.... Lane RM et al., published by " + "@HRBOpenRes" + ", https://hrbopenresearch.org/articles/8-40/v2" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/14082/15616") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "15616"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "46400": 0, "46401": 24, "46402": 0, "46403": 15, "46404": 0, "46405": 0, "48774": 0, "48584": 0, "48585": 0, "48586": 0, "48587": 0, "48588": 0, "48589": 0, "48590": 0, "48591": 0, "48534": 0, "48535": 3, "46396": 0, "46397": 0, "46398": 0, "46399": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "43614e6b-556f-4a37-be47-dfc0d4163fe5"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); Are you a HRB-funded researcher? Submission to HRB Open Research is open to all HRB grantholders or people working on a HRB-funded/co-funded grant on or since 1 January 2017. Sign up for information about developments, publishing and publications from HRB Open Research. First Name * You must provide your first name Last Name * You must provide your last name Email * You must provide a valid email address Institution You must provide an institution. Submit Thank you! We'll keep you updated on any major new updates to HRB Open Research HRB Open Research Browse How to Publish About Contact RSS Cookie Notice Privacy Notice Legal Submit Your Research © F1000 Research Limited and its licensors ISSN 2515-4826 | Legal background var F1000platform = new F1000.Platform({ name: "hrb", displayName: "HRB Open Research", hostName: "hrbopenresearch.org", id: "5", editorialEmail: "[email protected]", infoEmail: "[email protected]" }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); }); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'a006efac8f080db4',t:'MTc3OTU2OTQ2MQ=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();